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The World Health Organization's Global Influenza 
Surveillance and Response System meets twice a 
year to generate a recommendation for the composi-
tion of the seasonal influenza vaccine. Interim vaccine 
effectiveness (VE) estimates provide a preliminary 
indication of influenza vaccine performance during 
the season and may be useful for decision making. 
We reviewed 17 pairs of studies reporting 33 pairs of 
interim and final estimates using the test-negative 
design to evaluate whether interim estimates can reli-
ably predict final estimates. We examined features of 
the study design that may be correlated with interim 
estimates being substantially different from their 
final estimates and identified differences related to 
change in study period and concomitant changes in 
sample size, proportion vaccinated and proportion 
of cases. An absolute difference of no more than 10% 
between interim and final estimates was found for 18 
of 33 reported pairs of estimates, including six of 12 
pairs reporting VE against any influenza, six of 10 for 
influenza A(H1N1)pdm09, four of seven for influenza 
A(H3N2) and two of four for influenza B. While we iden-
tified inconsistencies in the methods, the similarities 
between interim and final estimates support the util-
ity of generating and disseminating preliminary esti-
mates of VE while virus circulation is ongoing.
Introduction
Influenza vaccination is currently the main strategy for 
reducing the burden of influenza morbidity and mortal-
ity. Influenza viruses continuously evolve by undergo-
ing antigenic drift and the composition of influenza 
vaccines therefore varies each year to account for anti-
genic changes in circulating viruses. The inability to 
use randomised trials to measure the efficacy of the 
influenza vaccine each year has resulted in the use 
of observational studies to determine annual vaccine 
effectiveness. However, observational studies such as 
cohort or case control studies can be subject to a num-
ber of biases.
The test-negative design (TND) is increasingly being 
used to measure influenza vaccine effectiveness (VE). 
The theory and methodology behind the TND has been 
discussed in detail previously [1-3]. Briefly, patients 
presenting for medical attention with a respiratory 
infection are swabbed and tested for influenza. Those 
testing positive are the cases and those testing nega-
tive are the comparison group [3]. Laboratory end 
points such as PCR-confirmed influenza are preferred 
in the TND, rather than low-specificity endpoints which 
could lead to underestimation of the effect of vaccina-
tion [4].
This design is favoured for the reporting of mid-season 
estimates, which provide a preliminary indication of 
vaccine performance during the season [5-21]. Early 
VE estimates may be useful to public health authori-
ties in the event of a pandemic or in a season where 
VE appears to be low, to guide resource allocation or 
initiate additional preventive measures. Belongia et 
al. have shown that interim estimates can be reliable 
to within 10 percentage points of the final estimate 
[22], while Sullivan et al. demonstrated that estimates 
made in seasons with an early start showed greatest 
reliability to within 10 percentage points [19]. Jimenez-
Jorge et al. also found agreement between mid- and 
end-of-season estimates in their comparison over four 
seasons in Spain [23], supporting the use of interim 
estimates. However, studies of interim influenza VE 
estimates might be expected to ignore desired exclu-
sion criteria due to small sample sizes and incomplete 
data. The objective of this review is to examine differ-
ences in reported interim and final influenza vaccine 
effectiveness estimates derived by the test-negative 
design, with particular reference to changes in the 
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analytical approach used between interim and final 
estimation.
Methods
Search strategy
Studies reporting influenza VE estimates were initially 
retrieved from PubMed on 8 November 2013 as part of 
a review of test-negative studies which focused solely 
on final estimates, excluding interim estimates [24]. At 
that time, articles were searched using combinations 
of the following terms: (i) ‘influenza’ OR ‘flu’, (ii) ‘vac-
cine effectiveness OR ‘VE’, (iii) ‘test-negative’ OR ‘test 
negative’ OR ‘case-control’ OR ‘case control’.
We used the list of excluded papers to identify interim 
estimates for this review. In addition, a further search 
of PubMed, Medline, Web of Science and Embase was 
conducted on 19 December 2014 and updated on 5 
December 2015 using the above search terms as well 
as the following: (iv) ‘interim’ OR ‘mid-season’ OR ‘mid 
season’ OR ‘early estimates’.
Complementary to the online search, the reference lists 
of retrieved articles were reviewed to identify addi-
tional studies. Articles were also identified, between 
May 2012 and December 2015, from influenza email 
alerts from the Centre for Infectious Disease Research 
and Policy (CIDRAP, http://www.cidrap.umn.edu/). We 
excluded articles which did not use the test-negative 
design or were a re-analysis of data, end of season 
analyses without corresponding interim analyses and 
interim analyses without corresponding final analyses. 
Searches were limited to articles in English only.
The titles of all papers identified were independently 
screened by two authors (VKL and SGS). Abstracts of 
potentially relevant papers were reviewed for eligibil-
ity, and the full text of eligible articles was reviewed. 
Studies reporting interim effectiveness estimates for 
any type of influenza vaccine (trivalent inactivated, 
live-attenuated, monovalent, adjuvanted/non-adju-
vanted or unspecified) were considered.
Once all interim papers were identified, their corre-
sponding end-of-season report was located. This was 
a specific search using the author names, location 
and season of the interim paper to identify the paper 
reporting final estimates.
Data retrieval
Study design and analysis features were reviewed for 
each article using a standardised data collection form. 
Specific features reviewed included the study setting, 
source population, case definition (including whether 
acute respiratory illness or influenza-like illness was 
used and any restrictions on time since symptom 
onset) exposure definition (including any restrictions 
on the period between vaccination and symptoms 
onset), study period or season, timing of interim esti-
mates in relation to the peak (determined by reviewing 
the epidemic curve provided in final analyses), any 
other exclusions (e.g. patients with missing informa-
tion, children younger than a certain age), variables 
included in the model to estimate VE and their specifi-
cation, and reported interim and final VE estimates. If 
the methods referred to a previous paper, the methods 
in the previous paper were recorded. If the specifica-
tion of a variable was not mentioned, it was assumed 
that it had not been taken into consideration in the 
analysis. In some instances where information was not 
available, the authors were contacted to provide this 
information.
Comparison of interim and final estimates
The VE estimates reported by each interim/final study 
pair were plotted using forest plots and compared visu-
ally. Changes between interim and final estimates of 10 
or more percentage points were considered meaning-
ful differences [19,22]. The difference in VE estimates 
(ΔVE) between final and interim analyses was calcu-
lated. Confidence intervals were estimated using boot-
strapping and were based on each study’s standard 
error estimated from reported confidence intervals. 
We attempted to evaluate whether any design features 
were associated with ΔVE. This was done in two ways: 
(i) univariate linear regression, modelling each design 
feature explored on the absolute value of ΔVE, and (ii) 
logistic regression, where the outcome was a change 
in ΔVE of 10 or more percentage points. Multivariate 
models were explored using stepwise regression to 
identify which variables were most influential on the 
value of ΔVE or a change in ΔVE of 10 or more percent-
age points. We used stepwise regression to limit the 
size of the final model; given the small number of data 
points, a full model would have been overparameter-
ised. Akaike information criterion (AIC) were used to 
choose variables for the final model using the stepAIC 
package in R. Design features were specified as the 
absolute difference between interim and final estimate 
Figure 1
PRISMA flow diagram showing search strategy
-Final analysis only
-Re-analysis of data
-TND not used
-No corresponding 
 final analysis
-Unable to compare 
 interim and final 
 estimates
Interim studies with paired 
final studies
n=17
Interim studies identified
n=32
Titles reviewed
n=43
Interim studies identified from 
previous review [18]
n=18
Updated search
n=25
Excluded n=11
Excluded n=15
PRISMA: preferred reporting items for systematic reviews and 
meta-analyses; TND: test-negative design.
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for sample size, proportion positive, proportion of 
vaccinated non-cases, number of weeks studied and 
number of covariates in the model. For other design 
features, the change in variable specification was used 
as a predictor; this included a change in specification 
of calendar time, vaccination definition, exclusion cri-
teria related to time since onset, and statistical model. 
We also examined whether there was a change in the 
dominant strain during the season and whether the 
interim estimate was made before or after the peak. All 
analyses were performed using R version 3.1.3.
Results
Of the 43 interim studies reviewed (Figure 1), we located 
a corresponding final VE estimate for 17 [5-23,25-40].
The characteristics of the paired interim and final anal-
yses are summarised in Table 1. Studies were reported 
from North America, Europe and Australasia, with a 
total of 17 countries represented. The 2013/14 final 
published estimate for Spain was included as part of 
analyses comparing interim and final estimates over a 
number of seasons [23]. Two interim reports published 
for the 2012/13 northern hemisphere season in the 
United States (US) were published one month apart. 
The first interim estimate [41] was excluded from the 
comparison as the number of cases was substantially 
smaller than those used in the second interim estimate 
for the season [7]. Three interim studies reported age-
specific estimates. No studies reported sex-specific 
estimates and only one interim study reported VE by 
risk group [16]. Eight northern hemisphere interim stud-
ies [5,6,13-15,17,18,21] and one southern hemisphere 
study [10] were published before or during the World 
Health Organization’s (WHO) vaccine strain selection 
meeting. 
Comparison of interim vs final vaccine 
effectiveness analyses
Interim and final study pairs were reviewed to identify 
differences within and between pairs in the methods 
used to make estimates. A summary of these changes 
is shown in Table 2.
Setting and source population
In none of the study pairs were there changes to the 
study setting between interim and final estimates. One 
pair of studies from New Zealand reported estimates 
for both community and hospital settings [20,37]. The 
source population differed in the final analyses of 
three studies where data were pooled from multiple 
surveillance networks or sites [31,33,36]. Pooled final 
estimates commonly included data from additional sur-
veillance sites which may not have had any cases at the 
time the interim estimate was made. For example, dur-
ing the European 2011/12 season some countries were 
unable to provide data for the interim estimate [12]. In 
general, sample sizes in final analyses of VE increased 
compared with the interim analyses. One interim study 
reported a larger sample size (n = 285 [19]) than the cor-
responding final estimate study (n = 262 [26]), which 
was associated with the application of stricter criteria 
for the definition of the study period used and subse-
quent exclusion of many non-cases.
Influenza-like illness definition
The clinical case definition used to identify patients was 
generally termed influenza-like illness (ILI); however 
in the US studies, acute respiratory illness (ARI) was 
used as the clinical case definition. The list of symp-
toms included in each definition remained the same 
between the interim study and final study in all but one 
pair [27]. The interim analysis for the 2010/11 season in 
Spain based the ILI definition on the International clas-
sification of primary care (ICPC) code for fever, whereas 
the final analysis provided a more specific definition 
for ILI. This did not appear to alter the point estimates 
for influenza A(H1N1)pdm09 (interim VE: 58%, 95% 
confidence interval (CI): 11–80; final VE: 59%, 95% CI: 
29–72) [5,27]. All studies included fever in the case 
definition for ILI, while only one study specified a tem-
perature-based definition [13].
Influenza case definition
Cases of influenza were defined differently in two pairs 
of interim and final analyses. The case definition used 
in the interim analysis for the 2010/11 season in the 
United Kingdom (UK) [14] included individuals with 
ILI who were swab-positive for any influenza, regard-
less of type or subtype. The definition used in the final 
analysis [36] only included individuals who were swab-
positive for influenza A(H1N1)pdm09 or influenza B. 
Conversely, Kissling et al. [12] included only patients 
who were positive for influenza A(H3N2) in their interim 
analysis, while the case definition for the final analysis 
included all patients who were swab-positive for any 
influenza [33]. However, the final analysis was later 
restricted to influenza A(H3N2) as this was the pre-
dominant circulating subtype during the season. Their 
end-of-season point estimate for influenza A(H3N2) 
decreased by 18 percentage points from the interim 
estimate (interim VE: 43%, 95% CI: 0–68; final VE: 
25%, 95% CI: −6 to 47).
Exposure
The classification of patients as vaccinated generally 
did not differ within study pairs. The definition for vac-
cination was not reported in the interim analysis for the 
Australian 2009 season [10]. In the final analysis [30], 
the vaccinated population was restricted to those pre-
senting 14 days or more after vaccination.
Study periods
The criteria used to define the start of the study 
period for interim analyses varied among studies. 
Two studies started with the commencement of sur-
veillance [10,19], six started when there was evidence 
of circulation based on laboratory-confirmed cases 
[5-8,16,20]. Five studies used only the weeks with 
cases, a certain period after the vaccination campaign 
[11,12,17,18,21,42], while four studies did not clearly 
define their study period [9,13-15].
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Table 1
Studies reporting interim and corresponding final influenza vaccine effectiveness estimates (n = 34)
Reference Study Interim/ final
Influenza 
season Country Types of patients Target groups Vaccine
[6] CDC 2008 Interim 2007/08 United States Inpatients and outpatients All ages TIV
[22] Belongia et al. 2011 Final 2007/08 United States Inpatients and outpatients All ages TIV
[10] Kelly et al. 2009 Interim 2009 Australia Outpatients All ages TIV
[30] Kelly et al. 2011 Final 2009 Australia Outpatients All ages TIV
[5] Castilla et al. 2011 Interim 2010/11 Spain Inpatients and outpatients
Target group 
for vaccination TIV, MIV
[27] Castilla et al. 2012 Final 2010/11 Spain Inpatients and outpatients
Target group 
for vaccination TIV, MIV
[42] Kissling et al. 2011 Interim 2010/11 Europe Outpatients All ages TIV
[32] Kissling et al. 2011 Final 2010/11 Europe Outpatients Target group for vaccination
TIV, 
adjuvanted 
vaccine
[14] Pebody et al. 2011 Interim 2010/11 United Kingdom Outpatients All ages TIV, MIV
[36] Pebody et al. 2013 Final 2010/11 United Kingdom Outpatients All ages TIV, MIV
[16] Savulescu et al. 2011 Interim 2010/11 Spain Outpatients Target group for vaccination TIV, AMIV
[29] Jimenez-Jorge et al. 2012 Final 2010/11 Spain Outpatients Target group for vaccination TIV, MIV
[12] Kissling et al. 2012 Interim 2011/12 Europe Outpatients Target group for vaccination TIV
[33] Kissling et al. 2013 Final 2011/12 Europe Outpatients Target group for vaccination TIV
[21] Valenciano et al. 2013 Interim 2012/13 Europe Outpatients Target group for vaccination TIV
[31] Kissling et al. 2014 Final 2012/13 Europe Outpatients Target group for vaccination TIV
[7] CDC 2013 Interim 2012/13 United States Outpatients All ages TIV
[34] McLean et al. 2014 Final 2012/13 United States Outpatients All ages TIV
[13] McMenamin et al. 2013 Interim 2012/13 United Kingdom Outpatients Target group for vaccination TIV
[25] Andrews et al. 2014 Final 2012/13 United Kingdom Outpatients All ages TIV
[19] Sullivan et al. 2013 Interim 2013 Australia Outpatients All ages TIV
[26] Carville et al. 2015 Final 2013 Australia Outpatients All ages TIV
[18] Skowronski et al. 2013 Interim 2012/13 Canada Outpatients All ages TIV
[39] Skowronski et al. 2014 Final 2012/13 Canada Outpatients All ages TIV
[43] Skowronski et al. 2014 Interim 2013/14 Canada Outpatients All ages TIV
[38] Skowronski et al. 2015 Final 2013/14 Canada Outpatients All ages
TIV, LAIV, 
adjuvanted 
TIV
[15] Pebody et al. 2015 Interim 2014/15 United Kingdom Outpatients All ages TIV
[35] Pebody et al. 2015 Final 2014/15 United Kingdom Outpatients All ages TIV, LAIV
[8] Jimenez-Jorge et al. 2012 Interim 2011/12 Spain Outpatients
All ages, target 
group for 
vaccination
TIV
[28] Jimenez-Jorge et al. 2013 Final 2011/12 Spain Outpatients
All ages, target 
group for 
vaccination
TIV
[9] Jimenez-Jorge et al. 2014 Interim 2013/14 Spain Outpatients All ages TIV
[23] Jimenez-Jorge et al. 2015 Final 2013/14 Spain Outpatients All ages TIV
[20] Turner et al. 2014 Interim 2014 New Zealand Inpatients and outpatients All ages TIV
[37] Pierse et al. 2015 Final 2014 New Zealand Inpatients and outpatients All ages TIV
AMIV: adjuvanted monovalent influenza vaccine; CDC: Centers for Disease Control and Prevention; LAIV: live-attenuated influenza vaccine; 
MIV: monovalent influenza vaccine; TIV: trivalent influenza vaccine.
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In general, the study period was defined in the same 
manner for final estimates, and the majority (n = 15) 
of studies commenced their study period on the same 
date for both interim and final analyses. In Spain in 
2010/11, the interim analysis commenced in October, 
while the final analysis used data only from early 
December; the interim and final VE estimates made 
for influenza A(H1N1)pdm09 against trivalent influ-
enza vaccines (TIV) and monovalent influenza vaccines 
(MIV) were within 10 percentage points of each other 
[5,27]. Conversely, the study period reported for the 
European 2011/12 final analysis commenced earlier 
than the study period of the interim analysis, and larger 
variation between the estimates for influenza A(H3N2) 
was observed (VE: 43%, 95% CI: 0–68% [12] vs VE: 
25%, 95%CI: −6 to 47% [33], respectively). In Australia 
in 2013, while the interim and final studies listed the 
same commencement date, the interim estimate was 
based on all available data for the surveillance period, 
while the final estimate was based on the weeks with 
cases and non-cases; thus the effective start date dif-
fered. The final estimate for all influenza (55%, 95% 
CI: −11 to 82) in that study pair [26] increased by 12 
percentage points compared with the interim estimate 
(43%, 95% CI: −30 to 75) [19].
Outcome
Among interim studies, patients were restricted to 
those presenting within four [10], seven [6,7,15,17-20], 
eight [8,9,11,12,16,21] or 29 days [13,14], while in one 
study, no such restrictions were mentioned [5]. These 
same restrictions applied in the final analyses in all but 
two studies. The interim estimate for the 2010/11 sea-
son in Spain restricted analyses to patients swabbed 
within eight days of symptom onset [16], whereas the 
final analyses was further restricted to within four days 
of symptom onset [8]. Similarly the 2012/13 season in 
the UK applied a restriction of less than 29 days for 
their interim analysis [13] and altered the cut-off to 
less than seven days for the final analysis [25]. In both 
the Spanish and UK studies, final VE estimates were 
decreased compared with the interim estimates.
Variables included in the model to estimate vaccine 
effectiveness
Interim and final estimates for all influenza (n = 12 
studies) and for influenza A(H1N1)pdm09 (n = 10 stud-
ies) were most commonly reported, while seven stud-
ies reported estimates for influenza A(H3N2) and four 
studies reported estimates for influenza B. All studies 
used logistic regression to estimate VE. Compared with 
interim analyses (which used between one and nine 
variables), end-of-season VE models used between 
two and 10 variables. Differences in the variables 
included in regression models were noted in 12 of the 
paired studies.
All estimates were adjusted for age, specified as a 
categorical variable. The specification of age changed 
between interim and final analysis for six study pairs, 
either by the use of different categories [22,26,27], 
re-specification as 10-year bands [32] or using cubic 
splines [31,34].
Calendar time was included in the model for 15 interim 
and corresponding final analyses. This variable was 
described in final analyses as a phase or period 
[27,30,34], week of swabbing, enrolment or symptom 
onset [22,23,28,29,31-33,38,39], month of sample col-
lection or symptom onset [25,35,36], or time relative to 
peak [26,37]. It was not included for two interim stud-
ies [7,10] but subsequently included in the model to 
estimate end-of-season VE [30,34]. The definition of 
calendar time varied in three pairs of interim and final 
analyses. In the model used to estimate interim VE 
for the 2012/13 European season, month of symptom 
onset was included as the calendar time variable [21], 
while week of symptom onset was used in the final 
model instead [31]. In both the Australian 2013 and 
New Zealand 2014 studies, week of presentation was 
used in interim analyses [19,20], while time relative to 
peak was used in the final analyses [26,37].
Seven study pairs included some adjustment for the 
presence of chronic medical conditions in both interim 
and final analyses, while five included this adjustment 
only in the final analysis [25-27,34,37].
Hospitalisation in the previous year, outpatient visits 
in the previous year and previous receipt of pneumo-
coccal vaccine were included in the model to estimate 
end-of-season VE of one study, but were not included 
for adjustment in the interim analysis [5]. Another 
study adjusted for days from illness onset to enrol-
ment, self-rated health and race/ethnicity [7] in the 
interim analysis, but did not adjust for these variables 
in their final analyses. Other variables included in both 
interim and final analyses included location or study 
site [5,7,11,13-15,17,18,25,27,32,34-36,38,39], history of 
smoking [8,11,28,32], receipt of previous influenza vac-
cine [11,16,29,32] and children in the household [5,27]. 
Comparison of interim and final vaccine 
effectiveness estimates
Interim and final VE estimates by type and subtype are 
shown in Figure 2–5.
In general, mid-season estimates were higher than 
end-of-season estimates. An absolute difference of less 
than 10 percentage points between interim and final 
estimates was found for 18 of 33 reported pairs of esti-
mates, including five of 12 pairs reporting VE against 
any influenza, six of 10 for influenza A(H1N1)pdm09, 
four of seven for influenza A(H3N2) and two of four for 
influenza B. The largest difference between interim and 
final estimates was observed in the 2008/09 season in 
the US (interim VE: −35%, 95% CI:-172 to 33 [6]; final 
VE: 31%, 95% CI: 3–51 [22]). In contrast, there were no 
changes to the point estimates for influenza A(H1N1)
pdm09 in the 2009 Australian season [10,30] and for 
influenza A(H3N2) in the 2012/13 European season 
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[21,31]. However, all interim and final estimates com-
pared displayed overlapping confidence intervals.
Univariate linear regression models suggested that 
only the proportion of vaccinated non-cases had a 
significant effect on the value of ΔVE (Table 3). The 
multivariate model identified that the proportion of 
vaccinated non-cases, change in how calendar time 
was specified and whether the interim estimate was 
made before the peak were the most influential varia-
bles; these were retained in the stepwise model. Using 
logistic regression, no design feature was identified as 
being statistically associated with a change in ΔVE of at 
least 10 percentage points in the univariate models. 
The stepwise model identified sample size, the propor-
tion positive, the number of weeks studied, the propor-
tion of vaccinated non-cases and whether the interim 
estimate was made before the peak as the most influ-
ential factors.
Discussion
We reviewed 17 pairs of published interim and final 
influenza VE studies that used the test-negative design 
to evaluate whether interim estimates can reliably 
predict final estimates. In general, interim estimates 
closely approximated final estimates, with 18 of 33 final 
estimates for all types and subtypes reported within 10 
percentage points of their corresponding interim esti-
mate. We attempted to explain discordance between 
pairs by examining their methodological differences 
and identified some inconsistencies between interim 
and final estimation. Within many of the study pairs, 
definitions for ILI, fever, study population, vaccination 
status, and the cut-off applied to the duration between 
patient presentation and symptom onset remained 
the same. The major differences were related to the 
change in study period and the concomitant changes 
in sample size, proportion vaccinated and proportion 
positive. In the two stepwise models we attempted, the 
variables identified as important predictors differed, 
with the exception of whether the interim estimate was 
Table 3
Summary of changes in study characteristics that influenced differences in vaccine effectiveness estimates
Characteristic
Linear model of ΔVE Logistic model of ΔVE > 10%
Univariate Multivariable Univariate Multivariable
β (se) pa β (se) pa OR (95% CI) p
b OR 
(95%CI) p
b
Intercept NA NA −0.2046 (3.42) 0.95 NA NA
4.55 
(0.9–63.24) NR
Sample size 0.0003 (0.0027) 0.9 NR NR
1 
(1–1) 0.7
1.001 
(1.0001–1.002) 0.07
Proportion of cases −0.17 (0.37) 0.7 NR NR
1.09 
(1–1.21) 0.1
1.13 
(1–1.34) 0.07
Proportion of non-cases vaccinated 1.85 (0.61) 0.005 1.68 (0.56) 0.006
1.07 
(0.92–1.27) 0.4 NA NR
Number of additional weeks in final estimate −0.19 (0.24) 0.4 NR NR
0.92 
(0.78–1) 0.2
0.85 
(0.67–0.95) 0.04
Number of covariates −0.08 (0.94) 0.9 NR NR
1.04 
(0.84–1.31) 0.7 NA NR
Change in calendar time specification (yes/no) −12.03 (5.95) 0.05
−13.97 
(5.51) 0.02
1.43 
(0.35–
5.98)
0.6 NA NR
Change to vaccination definition (yes/no) 36.13 (11.21) 0.4 NR NR
1.07 
(0.04–
28.62)
0.6 NA NR
Change to restriction on duration of illness (yes/no) −4.47 (10.72) 0.7 NR NR
0.5 
(0.02–
5.77)
0.6 NA NR
Estimate made pre-peak (pre/post) 5.83 (7.94) 0.5 13.03 (7.48) 0.09
0.46 
(0.06–2.8) 0.4
0.04 
(0–0.67) 0.06
Change to predominant strain (yes/no) −2.19 (12.95) 0.9 NR NR Inest Inest NA NR
Any change to model specification (yes/no) −9.18 (6.54) 0.2 NR NR
0.69 
(0.16–
2.98)
0.6 NA NR
β: regression coefficient; CI: confidence interval; ΔVE: difference in vaccine effectiveness estimates; inest: inestimable; NA: not applicable; 
NR: not retained; OR: odds ratio; se: standard error for the coefficient.
a In linear models, p was measured by t-test.
b In logistic models, p was measures by chi-square test.
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made before or after the peak of the season. A previ-
ous study comparing interim and final estimates in 
Victoria, Australia, suggested that interim estimates 
may be most reliable when made after the peak of the 
influenza season, which was attributed to the gain in 
sample size when estimates are made later in the sea-
son. However, such a clear trend was not identified in a 
similar analysis performed in Spain [23].
Differences between interim and final estimates were 
most noticeable for estimates made against any influ-
enza and influenza B. That concordance was better 
within subtypes possibly reflects how the summary 
estimate is influenced by individual specific type/sub-
type estimates as their prevalence changes through-
out the season. Although we did not find a change in 
dominant strain to be an important predictor of ΔVE, 
we were unable to capture the more subtle influence 
of changes in the proportionate mix of types/subtypes 
as the seasons progressed. We also noted that final 
estimates were generally lower than interim estimates, 
which raises questions about waning vaccine effective-
ness as the season progresses.
The largest methodological differences within study 
pairs were in the specification of the statistical model. 
When we examined whether a change to the regression 
model was associated with a change in the VE esti-
mate, we found no statistical difference. This is con-
sistent with findings from Victoria, Australia, where it 
was noted that estimates varied only slightly when the 
model used for final estimates was modified [19], and 
raises the question of whether it is necessary to adjust 
for additional variables just because they are availa-
ble. In studies of VE, we are trying to estimate a causal 
effect [24]. Thus, it could be argued that in principle, 
the model used for calculating VE should be decided a 
priori and should not change between interim and final 
estimation. We acknowledge that important informa-
tion on known confounders may be incomplete when 
calculating interim estimates. In such cases, one must 
be mindful of statistical biases, such as biases associ-
ated with complete-case analysis, where missing data 
may not be missing at random, or sparse data, both 
of which can result in a loss of precision and inflated 
estimates. However, the use of identical methods pro-
vides an assurance that heterogeneity between interim 
and final estimates is not due to methodological dif-
ferences and permits focus on other possible causes, 
such as the change in virus circulation and waning VE. 
As a minimum, reports should include in their sensi-
tivity analyses a comparison of interim and final esti-
mates using an identical analytical approach.
The results of our regression should be interpreted 
with caution. Firstly, the number of pairs available was 
probably insufficient to detect important associations, 
and certainly a multivariate model containing all pre-
dictors would have been overparameterised. With only 
33 observations in the model, a change in value of any 
one predictor could substantially change the size and 
importance of the association estimated. We were also 
unable to explore any interactions and it is likely that 
the effect of any of predictors explored would vary 
across levels of other predictors. Secondly, although a 
study may have reported a certain study period, this 
did not necessarily correspond to the date range of 
the observations used in the VE estimation. This was 
noted in the 2013 studies in Australia, but could also 
happen as a consequence of covariate specification. 
For example, specification of week as a categorical 
variable can lead to perfect prediction [43] and loss 
of observations from weeks without both a case and 
a non-case. Truncation of the data by the regression 
programme will result in the loss of observations and 
reported sample sizes may therefore be misleading. 
Thus, it is possible that some of the predictors speci-
fied in our regression models were incorrectly calcu-
lated. Finally, we calculated ΔVE based on each study’s 
point estimate only. Although ΔVE was calculated with 
a confidence interval, our regression models focussed 
on the median only. We did not exclude studies with 
large confidence intervals because their width is tied 
to sample size, which was one of the factors we were 
interested in exploring.
Interim estimates provide an early snapshot of the 
influenza vaccine’s effectiveness during a season, but 
their validity and reliability needs to be assured. End-
of-season estimates have advantages over interim esti-
mates in terms of gains in sample size and the longer 
time available to undertake the analysis. However, they 
typically take more than six months to publish, which 
is well beyond their usefulness for policy. Interim 
estimates are also more useful than final estimates 
for decision making around vaccine composition. The 
WHO’s Global Influenza Surveillance and Response 
System meets twice a year to generate a recommenda-
tion for the composition of the seasonal vaccine. Since 
February 2013, interim and final VE estimates gener-
ated from surveillance data have been presented at 
this meeting [44]. The utility of VE estimates in strain 
composition is limited to scenarios where the virologi-
cal and serological data are inconclusive, there are 
suitable, alternative candidates vaccine viruses, and 
VE suggests poor performance of the current compo-
nent. However, because of their timeliness, it is the 
interim, not the final, VE estimates that are informative 
in such a scenario.
Given the potential utility of interim VE estimates and 
the variability between methods used to estimate 
interim and final VE, it would be worthwhile imple-
menting the use of a standard model for estimating 
interim VE. Such a model might include a minimum set 
of known confounders in the statistical model, use of 
standardised inclusion criteria, and minimum sample 
size and/or standard error requirements. In conduct-
ing this review, we identified inconsistencies in the 
way data are reported, particularly case and vaccina-
tion status, highlighting the need for a standardised 
reporting template. The similarities observed between 
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interim and final estimates support the feasibility of 
generating and disseminating preliminary estimates of 
VE while virus circulation is ongoing.
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